Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,499.60
(
0.38%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
72,859.45
(
-0.16%
)
News Focus
News Focus
Post# of 257382
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122860
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 228599

Thursday, 03/26/2020 5:32:53 PM

Thursday, March 26, 2020 5:32:53 PM

Post# of 257382
ABUS reports interim phase-1 data on AB-729 for HBV:

https://finance.yahoo.com/news/arbutus-announces-positive-preliminary-phase-200510591.html

AB-729 is an injected RNAi agent that targets HBsAg. The data reported today are from a single subcutaneous dose.

After 29 days, the mean reduction in HBsAg was: 0.2 logs in the 60mg cohort; and 0.8 logs in the 180mg cohort.

After 12 weeks, the mean reduction in HBsAg was: n/a in the 60mg cohort; and -1.0 logs in the 180mg cohort.

Whether HBsAg is the right target to be hitting is somewhat controversial—see, for instance, #msg-152274693.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today